Sanara MedTech opened higher at $31.81, compared with its previous close of $31.61. In the last trading session, the stock traded between $31.81 and $32.71. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sanara MedTech is now worth
$ 95.18
Resulting in a loss of
$ 4.82 (4.82%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
+$0.90 (+2.83%)
Day High
$32.71
Day Low
$31.81
Day Open
$31.81
Prev Close
$31.61
Volume
58,982
1W Return
0.70%
1M Return
-7.56%
3M Return
-5.35%
6M Return
80.38%
1Y Return
15.92%
Fundamentals
Market Cap ($ Mn)
299
PE Ratio
-
PB Ratio
40.03
PEG Ratio
-
ROE
-1.59%
ROCE
9.15%
EPS (TTM)
$-0.05
Investment Returns
1 Week
0.70%
1 Month
-7.56%
3 Months
-5.35%
6 Months
80.38%
9 Months
66.52%
Financials
Quarterly
All values in $ Mn
23.4
Mar 25
25.8
Jun 25
26.3
Sep 25
27.5
Dec 25
27.8
Mar 26
28.1
Jun 26
Updates
29Aug
Halper Sadeh probes Sanara MedTech sale to MiMedx for fair value
Halper Sadeh LLC investigates Sanara MedTech's sale to MiMedx for fair shareholder value. Proposed deal offers $33.00 cash and 0.4735 MiMedx shares per Sanara share. Probe cites potential fiduciary breaches and insider benefit conflicts. Firm seeks increased consideration or additional disclosures on a contingent fee basis.
Sanara MedTech’s Q2 results show a complex financial landscape with revenue growing 8.93% YoY to $28.137 million, but EPS missing estimates significantly at $(0.05). The company narrowed its YoY loss per share by 78.26%, yet failed to meet the $0.02 profit expectation, highlighting persistent margin challenges despite top-line gains.
3mo ago
4Aug
Kahn Swick & Foti joins probe into Sanara MedTech-MiMedx deal
Kahn Swick & Foti, LLC has joined an ongoing investigation into the proposed acquisition of Sanara MedTech Inc. by MiMedx Group, Inc., alleging potential undervaluation and fiduciary breaches. The deal offers $35 per share, comprising $33 in cash and stock, amid scrutiny from multiple law firms regarding insider benefits and process transparency.
